EMA Authorised: Cystagon (mercaptamine bitartrate) — Recordati Rare Diseases

View source ↗

Summary

The EMA authorised Cystagon (mercaptamine bitartrate) for the treatment of cystinosis, with Recordati Rare Diseases as the marketing authorization holder; decis…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cystinosis

Drugs mentioned

• Cystagon (cysteamine bitartrate)

Snippet

Status: Authorised. Therapeutic area: Cystinosis. MAH: Recordati Rare Diseases. Decision date: 10/12/2024